Alterity Therapeutics Ltd. is a clinical stage biotechnology company. The company is headquartered in Melbourne, Victoria. The company went IPO on 2000-03-28. The firm is focused on developing disease modifying treatments for neurodegenerative diseases. The firm's lead asset, ATH434, is to treat various Parkinsonian disorders. ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. The company has the potential to treat Parkinson's disease, as well as various Parkinsonian disorders, such as Multiple System Atrophy (MSA). The firm also has a drug discovery platform generating patentable chemical compounds to intercede in disease processes. ATH434 has been granted Orphan designation for the treatment of MSA. The Phase II clinical trial is a randomized, double-blind, placebo-controlled investigation of ATH434 in patients with early-stage MSA.
Follow-Up Questions
What is the price performance of ATHE stock?
The current price of ATHE is $4.86, it has decreased 0.47% in the last trading day.
What are the primary business themes or industries for Alterity Therapeutics Ltd?
Alterity Therapeutics Ltd belongs to Biotechnology industry and the sector is Health Care
What is Alterity Therapeutics Ltd market cap?
Alterity Therapeutics Ltd's current market cap is $88.2M
